
    
      This protocol will evaluate the safety of CMV specific T cell infusion following
      nonmyeloablative stem cell transplantation from 3-6/6 HLA matched donors as well as evaluate
      the efficacy of antigen specific T cell infusions in preventing CMV activation.
    
  